FDA to hold public hearings on CBD in April
Food and Drug Administration (FDA) will hold public hearings on CBD in April, according to statements made by FDA Commissioner Scott Gottlieb, during a recent House Appropriations subcommittee hearing. The purpose of the public hearing will be to start the rule-making process and gather stakeholder input on how the FDA can regulate hemp-derived CBD.
In addition, FDA will form a working group of senior officials and agency experts to advise the Commissioner on regulatory options. Gottlieb affirmed Congress wants a path for regulating food and dietary supplements containing CBD. Gottlieb said, “this is not a straightforward process. There’s not a good proxy for us doing this through regulation.”
The conceptual regulatory framework includes a pharmaceutical path and a path for food products and dietary supplements. Gottlieb specifically mentions FDA approved CBD epilepsy medication, Epidiolex and wanting to maintain a motivation to study CBD for pharmaceutical products by keeping a pharmaceutical regulatory framework.
Although Gottlieb declared his attention to the complexities of regulating CBD, he recently announced his April resignation for personal reasons, almost a year after his appointment as FDA Commissioner.
McAllister Garfield, P.C. is busy advising hemp and CBD companies during this time of transition. For more information, contact McAllister Garfield today.
Related Article
Psychedelic Therapy & Law Update – November 2025
Colorado Regulator Releases updated NMHA Screening Forms Colorado’s primary NMHA regulator, DORA, recently released new and updated model forms for work in the regulated area. These forms include 12 recommended forms to comply with the rules along with guidance documents and checklists for using the forms. All of the updated state forms can be found here. […]
Psychedelic Therapy & Law Update – October 2025
Clarification of Facilitator’s Right to Handle Medicine under NMHA In the Colorado regulated NMHA healing center context, the rules say that licensed Facilitators can administer natural medicine to participant, but how broad is the term administer? Can Facilitators for example move medicine from a secure area and hand it to a participant? This created some […]
Psychedelic Therapy & Law Update – September 2025
Slow start to NMHA Program, but Iboga (ibogaine) added As of mid-September, 2025, the regulated program under Natural Medicine Health Act has only 5 approved full healing centers in Colorado. Sixteen micro-healing centers have been approved to date. Healing centers are not required to report their number of journeys until the end of the year, […]